Gossamer Bio (NASDAQ:GOSS) Given Buy Rating at Chardan Capital

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a note issued to investors on Monday, Benzinga reports.

A number of other equities research analysts also recently weighed in on GOSS. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $9.60 on Monday. The firm’s 50-day moving average is $11.48 and its 200-day moving average is $16.16. The company has a market cap of $58.67 million, a price-to-earnings ratio of -0.17 and a beta of 2.21. Gossamer Bio has a 52-week low of $8.29 and a 52-week high of $309.60.

Institutional Trading of Gossamer Bio

Several institutional investors have recently made changes to their positions in GOSS. Corient Private Wealth LP raised its position in Gossamer Bio by 41.3% in the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after purchasing an additional 1,647,315 shares in the last quarter. Bank of America Corp DE bought a new position in Gossamer Bio during the second quarter worth about $65,000. Hsbc Holdings PLC lifted its stake in Gossamer Bio by 1,289.4% during the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after purchasing an additional 1,469,175 shares during the period. Kalehua Capital Management LLC acquired a new stake in Gossamer Bio during the first quarter valued at approximately $3,363,000. Finally, Hhlr Advisors LTD. bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $819,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.